MedDataX Logo

Study Evaluating ERB-041 in Endometriosis in Reproductive-Age Women

NCT ID: NCT00110487

Last Updated: 2015-05-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-01-31

Study Completion Date

2006-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this investigational study is to determine if a study medication is safe and effective in reducing the symptoms associated with endometriosis; if the study medication reduces the need for pain medication for endometriosis symptoms; and if the study medication improves a participant's ability to carry out daily activities. Qualified participants will receive no cost treatment, which may include study-related examinations, diagnostic procedures including a Pap smear, laboratory testing, and a mammogram (aged 40-45). Qualified participants will also receive study medication at no cost. As a participant, the study volunteer may also experience the satisfaction of knowing she is helping the advancement of women's health care.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study Evaluating the Safety and Efficacy of ERB-041 on Reduction of Symptoms Associated With Endometriosis in Reproductive-Aged Women

NCT00318500

Dysmenorrhea Dyspareunia Endometriosis +1 more
COMPLETED PHASE2

Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis

NCT03481842

Endometriosis Endometriosis Ovary Endometriosis Externa +1 more
WITHDRAWN PHASE1/PHASE2

Evaluation of DR-2001 for the Management of Endometriosis-Related Pelvic Pain

NCT00117481

Endometriosis
COMPLETED PHASE2

A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis

NCT01116440

Pelvic Pain Associated With Refractory Endometriosis
TERMINATED PHASE2

Study to Investigate the Efficacy of a Non-hormonal Drug Against Endometriosis Associated Pelvic Pain

NCT00185341

Endometriosis
COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Endometriosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ERB-041

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Surgical diagnosis of endometriosis within 5 years
* Not pregnant and not lactating
* Willing to use non-hormonal contraception, history of regular menstrual cycles

Exclusion Criteria

* Hysterectomy, surgical treatment for endometriosis within 3 months
* Certain medications for the treatment of endometriosis
* Previous history of a malignancy
* Abnormalities on physical or gyn exams and abnormal lab tests
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Monitor

Role: STUDY_DIRECTOR

Wyeth is now a wholly owned subsidiary of Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Phoenix, Arizona, United States

Site Status

Tucson, Arizona, United States

Site Status

Carmichael, California, United States

Site Status

La Jolla, California, United States

Site Status

Redding, California, United States

Site Status

San Diego, California, United States

Site Status

Lakewood, Colorado, United States

Site Status

Aventura, Florida, United States

Site Status

Boynton Beach, Florida, United States

Site Status

Celebration, Florida, United States

Site Status

Clearwater, Florida, United States

Site Status

Miami, Florida, United States

Site Status

Miami, Florida, United States

Site Status

New Port Richey, Florida, United States

Site Status

Ocala, Florida, United States

Site Status

Palm Harbor, Florida, United States

Site Status

Alpharetta, Georgia, United States

Site Status

Atlanta, Georgia, United States

Site Status

Arlington Heights, Illinois, United States

Site Status

Champaign, Illinois, United States

Site Status

Chicago, Illinois, United States

Site Status

Chicago, Illinois, United States

Site Status

Oak Brook, Illinois, United States

Site Status

South Bend, Indiana, United States

Site Status

Shreveport, Louisiana, United States

Site Status

Lanham, Maryland, United States

Site Status

Laurel, Maryland, United States

Site Status

Detroit, Michigan, United States

Site Status

Chaska, Minnesota, United States

Site Status

Chesterfield, Missouri, United States

Site Status

Las Vegas, Nevada, United States

Site Status

Berlin, New Jersey, United States

Site Status

Charlotte, North Carolina, United States

Site Status

Fargo, North Dakota, United States

Site Status

Cincinnati, Ohio, United States

Site Status

Cleveland, Ohio, United States

Site Status

Eugene, Oregon, United States

Site Status

Greenville, South Carolina, United States

Site Status

Greer, South Carolina, United States

Site Status

Dallas, Texas, United States

Site Status

Fort Worth, Texas, United States

Site Status

Webster, Texas, United States

Site Status

Sandy City, Utah, United States

Site Status

Norfolk, Virginia, United States

Site Status

Richmond, Virginia, United States

Site Status

Madison, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

3142A2-200

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study of Women Receiving Standard of Care (SOC) for the Treatment of Pelvic Pain Due to Suspected or Confirmed Endometriosis and the Impact on the Disease or Symptom Progression.
NCT04140175 TERMINATED
Pain Associated With Endometriosis
NCT00758953 COMPLETED PHASE2
Ulipristal for Endometriosis-related Pelvic Pain
NCT02213081 COMPLETED PHASE4
A Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain
NCT06963177 RECRUITING PHASE2
The Effect of Selective Oxytocin Receptor Inhibitors on Endometriosis-related Pain
NCT05382143 UNKNOWN PHASE2
A Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Investigate the Efficacy, Safety and Duration of Effect of a Single Administration of Various Doses of Cetrorelix SR in Subjects With Histologically Confirmed Endometriosis
NCT00244452 COMPLETED PHASE2
Endometriosis Trial: Study of NBI-56418 in Endometriosis
NCT00109512 COMPLETED PHASE2
Evaluate the Efficacy and Safety of HMI-115 in Women With Moderate to Severe Endometriosis-associated Pain
NCT07318688 NOT_YET_RECRUITING PHASE3
A Study to Assess the Efficacy and Safety of HMI-115 in Subjects With Endometriosis-Associated Pain
NCT05101317 COMPLETED PHASE2
Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain
NCT04372121 TERMINATED PHASE3
BGS649 Monotherapy in Moderate to Severe Endometriosis Patients
NCT01190475 COMPLETED PHASE2
Letrozole in the Treatment of Severe and Recurrent Endometriosis
NCT00240942 COMPLETED PHASE2
The Effectiveness of Laparoscopic Treatment of Superficial Endometriosis for Managing Chronic Pelvic Pain
NCT04081532 COMPLETED NA
Safety and Efficacy Study of MT-2990 in Women With Endometriosis
NCT03840993 COMPLETED PHASE2
The Pharmacokinetic(PK)/Pharmacodynamics(PD) Study of SHR7280 Tablets in Premenopausal Subjects With Endometriosis.
NCT04417972 COMPLETED PHASE1/PHASE2
A Study to Evaluate the Safety and Efficacy of BOL-DP-o-08 in Patients With Endometriosis Syndrome.
NCT04174911 WITHDRAWN PHASE1/PHASE2
A Randomized, Placebo-controlled, Double-blind Study of KLH-2109 in Patients With Endometriosis (2)
NCT01533532 COMPLETED PHASE2
Levonorgestrel-releasing Intrauterine System in Patients With Endometriosis
NCT02158845 COMPLETED PHASE4
Evaluation of a Nutraceutical for Endometriosis Pain Relief
NCT04091191 TERMINATED NA
Antilipidemic Ezetimibe Induces Regression of Endometriotic Explants in a Rat Model of Endometriosis
NCT04844996 COMPLETED EARLY_PHASE1
Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually Grows Inside the Womb Grows Outside of the Womb
NCT04614246 TERMINATED PHASE2
Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women With Moderate to Severe Endometriosis-associated Pain
NCT02143713 COMPLETED PHASE3
Resveratrol for Pain Due to Endometriosis
NCT02475564 COMPLETED PHASE4
Pelvic Pain in Women With Endometriosis
NCT00073801 COMPLETED
Study of the Efficacy and Safety of Longidaze® for the Treatment of Patients With External Genital Endometriosis
NCT04962620 UNKNOWN